Etanercept in the treatment of rheumatoid arthritis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 1, 2007, Pages 99-105

  Haraoui, Boulos ^a,c   Bykerk, Vivian ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

Author keywords

Etanercept; Psoriatic arthritis; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; ISONIAZID; LYMPHOTOXIN; METHOTREXATE; PLACEBO; RIFAMPICIN; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; APRAXIA; ARTHRITIS; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; CANDIDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONGESTIVE HEART FAILURE; CRYPTOCOCCOSIS; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; GAIT DISORDER; GUILLAIN BARRE SYNDROME; HISTOPLASMOSIS; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; LISTERIOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MALAISE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PARESTHESIA; PLEURISY; PNEUMOCYSTOSIS; POSTMARKETING SURVEILLANCE; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; STEADY STATE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

EID: 34247628404     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.1.99     Document Type: Review

References (35)

1. Askling J, Fored CM, Baeckland E, et al. 2005. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis, 64:1414-20.
2. Bathon JM, Martin RW, Fleischmann RM, et al. 2000. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med, 343:1586-93.
3. Beayert R, Fiers W. 1998. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis AR, Thorpe R (eds). Cytpkines 1st ed. London: Academic Pr, pp 235-60.
4. Belostocki KB, Leibowitz E, Tai K, et al. 200 1. Infections associated with etanercept treatment in rheumatoid arthritis: 2 years of experience in the "real-world" [abstract]. Arthritis Rheum, 44(Suppl):S173, 725.
5. Berg L, Lampa J, van Vollenhoven R, et al. 2001. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFa receptors. Ann Rheum Dis, 60:133-9.
6. Cartina AI, Lampa J, Ernestam S, et al. 2002. Anti tumor necrosis factor (TNF)-a therapy (etanercept) down regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatol, 41:484-9.
7. Cunnane G, Doran M, Bresnihan B. 2003. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol, 17:345-63.
8. De Rycke L, Baeten D, Kruithof E, et al. 2005. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum, 52:2192-201.
9. Fleischman RM, Baumgartner SW, Tindall EA, et al. 2003. Response to etanercept (Enbrel®) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol, 30:691-6.
10. Jonsdotter T, Forshid J, Vollenhoven A, et al. 2004. Treatment with tumor necrosis factor antagonists in patients with rheumatoid arthritis induced anticardiolipin antibodies. Ann Rheum Dis, 63:1075-8.
11. Keystone EC, Schiff MH, Kremer JM et al. 2005. Once-weekly administration of 50mg ctanercept in patients with active rheumatoid arthritis: Results ofa multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 50:353-63.
12. Klareskog L, van der Heijde D, de Jager JP, et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 363:675-81.
13. Korth-Bradley JM, Rubin AS, Hanna RK, et al. 2000. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother, 34:161-4.
14. Krakauer T, Vilcek J, Oppenheim JJ. 1999. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF-b, and others. In: Pauluis WE (ed). Fundamental immunology. 4th ed. Philadelphia: Lippincott-Raven, pp 775-811.
15. Locksley RM, Kileen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104:487-501.
16. Lubeck DP, Katz P, Yelin E et al. 2001. Long term impact of etanercept (Enbrel®) on health related quality of life and functional status of persons with rheumatoid arthritis [abstract]. Arthritis Rheum, 44(Suppl): S 184, 787.
17. Mann DL, McMurray JJ, Packer M, et al. 2004. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomised Etanercept World-wide Evaluation (RENEWAL). Circulation, 109:1594-602.
18. McDermott ME 2001. TNF and TNFR biology in health and disease. Cell Mol Biol, 47:619-35.
19. Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 356:385-90.
20. Mohan AK, Edwards ET, Cote TR, et al. 2002. Drug induced systemic lupus and anti-TNF alpha blockers. Lancet, 360:646.
21. Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum, 44:2862-9.
22. Mohler KM, Torrance DS, Smith CA, et al. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 151:1548-61.
23. Moreland LW, Baumgartner SW, Schiff MH, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumournecrosis factor receptor (p75)-Fc fusion protein, N Engl J Med, 337:141-47.
24. Moreland LW, Bucy RP, Weinblatt ME, et al. 2002. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol, 103:13-21.
25. Osiri M, Suarez-Almazor ME, Wells GA, et al. 2003. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis, 62:316-21.
26. Phillips K, Husni ME, Karlson EW, et al. 2002. Experience with etanercept in an academic medical center: Are infection rates increased? Arthritis Care Res, 47:17-21.
27. Setoguchi S, Solomon DH, Weinblatt ME, et al. 2006. Tumor Necrosis Factor a use and cancer in patients with rheumatoid arthritis. Arthritis Rheum, 54:2757-64.
28. Shakoor N, Michalski M, Harris CA, et al. 2002. Drug induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 359:579-80.
29. Taggart AJ, van Riel PL, and Kekow J. 2005. Assessment of functional status and quality of life in a randomized study comparing etanercept and methotrexate with etanercept alone in patients with active rheumatoid arthritis despite mcthotrexate therapy: The ADORE study (abstract]. Arthritis Rheum, 52(Suppl):232, 550.
30. Verschueren PC, Markusse H, Smeets TJM, et al. 1999. Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (p75) in RA patients [abstract]. Arthritis Rheum, 42(Suppl):S197, 762.
31. Wasko MC. 2004. Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol, 16:109-13.
32. Weinblatt ME, Kremer JM, Bankhurst AD, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:fe fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 340:253-9.
33. Wolfe F, Michaud K. 2004a. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum, 50:1740-51.
34. Wolfe F, Michaud K. 2004b. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med, 116:305-11.
35. Yelin E, Katz P, Lubeck D et al. 2001. Impact of etanercept (Enbrel®) on health care use and employment in early RA [abstract]. Arthritis Rheum, 44(Suppl):S152, 59520.